Results 191 to 200 of about 103,219 (202)

Auf BRAF-Mutation testen!

InFo Hämatologie + Onkologie, 2019
openaire   +1 more source

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine, 2011
Paul B Chapman, Caroline Robert, James Larkin   +2 more
exaly  

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Cancer Cell, 2010
Jessie Villanueva, Adina Vultur, Damien Kee   +2 more
exaly  

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Cell, 2010
Steven R Whittaker, Nathalie Dhomen, Richard Marais   +2 more
exaly  

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

New England Journal of Medicine, 2010
Keith T Flaherty, Igor Puzanov, Kevin B Kim   +2 more
exaly  

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Cancer Cell, 2015
Eishu Hirata, Amaya Viros, Michiyuki Matsuda   +2 more
exaly  

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Cancer Cell, 2013
Rizwan Haq, Glenn C Rowe, Abhinav Nellore   +2 more
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
exaly  

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The, 2015
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Ziyu Chen, David B Solit
exaly